Trinity Biotech PLC (NASDAQ:TRIB) announced its quarterly earnings results on Thursday, July 20th. The company reported $0.03 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by $0.03, Morningstar.com reports. Trinity Biotech PLC had a positive return on equity of 5.54% and a negative net margin of 100.45%. The business had revenue of $25.45 million for the quarter, compared to analyst estimates of $24.83 million.
Trinity Biotech PLC (NASDAQ TRIB) traded up 0.085% during mid-day trading on Monday, hitting $5.865. 15,268 shares of the company traded hands. Trinity Biotech PLC has a one year low of $5.20 and a one year high of $13.68. The company’s 50-day moving average is $5.88 and its 200-day moving average is $5.91. The stock’s market capitalization is $128.13 million.
COPYRIGHT VIOLATION WARNING: This story was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://stocknewstimes.com/2017/07/31/trinity-biotech-plc-nasdaqtrib-issues-earnings-results-misses-estimates-by-0-03-eps-updated.html.
A number of institutional investors have recently modified their holdings of TRIB. GSA Capital Partners LLP bought a new position in Trinity Biotech PLC during the fourth quarter valued at approximately $170,000. Two Sigma Investments LP increased its position in Trinity Biotech PLC by 138.5% in the fourth quarter. Two Sigma Investments LP now owns 185,572 shares of the company’s stock valued at $1,284,000 after buying an additional 107,779 shares in the last quarter. Acadian Asset Management LLC bought a new position in Trinity Biotech PLC during the first quarter valued at approximately $286,000. Heartland Advisors Inc. increased its position in Trinity Biotech PLC by 0.8% in the first quarter. Heartland Advisors Inc. now owns 1,545,550 shares of the company’s stock valued at $9,211,000 after buying an additional 11,800 shares in the last quarter. Finally, US Bancorp DE increased its position in Trinity Biotech PLC by 3.1% in the first quarter. US Bancorp DE now owns 352,184 shares of the company’s stock valued at $2,099,000 after buying an additional 10,458 shares in the last quarter. Institutional investors and hedge funds own 65.41% of the company’s stock.
Several research analysts have recently commented on the stock. ValuEngine lowered shares of Trinity Biotech PLC from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research lowered shares of Trinity Biotech PLC from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th.
About Trinity Biotech PLC
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with MarketBeat.com's FREE daily email newsletter.
